Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR)

M. B. Grant, R. Mames, R. Cooper, S. Caballero, C. Fitzgerald

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose. The success of hypophysectomy as a treatment modality for proliferate DR correlates directly with the degree of GH deficiency achieved. The somatostatin analogue, OCT, decreases levels of growth hormone (GH) and the GH-related peptide, insulin-like growth factor-I (IGF-I). IGF-I mediates most of GH's mitogenic activity. We investigated the therapeutic efficacy of OCT in prevention of progression of DR in patients (pts) with either severe nonproliferative DR or non "high risk" proliferative DR. Methods. 16 diabetic pts were randomized to treatment (n=8)(continuous infusion or QID sub q administration of maximally tolerated OCT doses ranging from 600-3000 μg/day) or control (n=8)(conventional DM management) groups for 15 months. Pts received clinical and biochemical assessment at entry and at 3 month intervals. Ophthalmic assessment occurred at entry and at 1 month intervals. Seven fields per eye were assessed for characterization of retinopathy and grading using a modified ETDRS grading system. Results. In pts treated with OCT, GH levels (area under curve) were reduced by 33% (p1c, over 15 months was improved in the OCT treated group (6.4±0.9%) compared to the control group (8.1±1.2%)(p

Original languageEnglish (US)
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
StatePublished - Feb 15 1996
Externally publishedYes

Fingerprint

Octreotide
Diabetic Retinopathy
Growth Hormone
Insulin-Like Growth Factor I
Hypophysectomy
Maximum Tolerated Dose
Somatostatin
Area Under Curve
Therapeutics
Control Groups
Peptides

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Grant, M. B., Mames, R., Cooper, R., Caballero, S., & Fitzgerald, C. (1996). Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR). Investigative Ophthalmology and Visual Science, 37(3).

Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR). / Grant, M. B.; Mames, R.; Cooper, R.; Caballero, S.; Fitzgerald, C.

In: Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 15.02.1996.

Research output: Contribution to journalArticle

Grant, MB, Mames, R, Cooper, R, Caballero, S & Fitzgerald, C 1996, 'Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR)', Investigative Ophthalmology and Visual Science, vol. 37, no. 3.
Grant, M. B. ; Mames, R. ; Cooper, R. ; Caballero, S. ; Fitzgerald, C. / Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR). In: Investigative Ophthalmology and Visual Science. 1996 ; Vol. 37, No. 3.
@article{2c56143d4dde4891a3102de55dae9ab8,
title = "Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR)",
abstract = "Purpose. The success of hypophysectomy as a treatment modality for proliferate DR correlates directly with the degree of GH deficiency achieved. The somatostatin analogue, OCT, decreases levels of growth hormone (GH) and the GH-related peptide, insulin-like growth factor-I (IGF-I). IGF-I mediates most of GH's mitogenic activity. We investigated the therapeutic efficacy of OCT in prevention of progression of DR in patients (pts) with either severe nonproliferative DR or non {"}high risk{"} proliferative DR. Methods. 16 diabetic pts were randomized to treatment (n=8)(continuous infusion or QID sub q administration of maximally tolerated OCT doses ranging from 600-3000 μg/day) or control (n=8)(conventional DM management) groups for 15 months. Pts received clinical and biochemical assessment at entry and at 3 month intervals. Ophthalmic assessment occurred at entry and at 1 month intervals. Seven fields per eye were assessed for characterization of retinopathy and grading using a modified ETDRS grading system. Results. In pts treated with OCT, GH levels (area under curve) were reduced by 33{\%} (p1c, over 15 months was improved in the OCT treated group (6.4±0.9{\%}) compared to the control group (8.1±1.2{\%})(p",
author = "Grant, {M. B.} and R. Mames and R. Cooper and S. Caballero and C. Fitzgerald",
year = "1996",
month = "2",
day = "15",
language = "English (US)",
volume = "37",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - Octreotide (OCT) does not prevent progression of Diabetic Retinopathy (DR)

AU - Grant, M. B.

AU - Mames, R.

AU - Cooper, R.

AU - Caballero, S.

AU - Fitzgerald, C.

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Purpose. The success of hypophysectomy as a treatment modality for proliferate DR correlates directly with the degree of GH deficiency achieved. The somatostatin analogue, OCT, decreases levels of growth hormone (GH) and the GH-related peptide, insulin-like growth factor-I (IGF-I). IGF-I mediates most of GH's mitogenic activity. We investigated the therapeutic efficacy of OCT in prevention of progression of DR in patients (pts) with either severe nonproliferative DR or non "high risk" proliferative DR. Methods. 16 diabetic pts were randomized to treatment (n=8)(continuous infusion or QID sub q administration of maximally tolerated OCT doses ranging from 600-3000 μg/day) or control (n=8)(conventional DM management) groups for 15 months. Pts received clinical and biochemical assessment at entry and at 3 month intervals. Ophthalmic assessment occurred at entry and at 1 month intervals. Seven fields per eye were assessed for characterization of retinopathy and grading using a modified ETDRS grading system. Results. In pts treated with OCT, GH levels (area under curve) were reduced by 33% (p1c, over 15 months was improved in the OCT treated group (6.4±0.9%) compared to the control group (8.1±1.2%)(p

AB - Purpose. The success of hypophysectomy as a treatment modality for proliferate DR correlates directly with the degree of GH deficiency achieved. The somatostatin analogue, OCT, decreases levels of growth hormone (GH) and the GH-related peptide, insulin-like growth factor-I (IGF-I). IGF-I mediates most of GH's mitogenic activity. We investigated the therapeutic efficacy of OCT in prevention of progression of DR in patients (pts) with either severe nonproliferative DR or non "high risk" proliferative DR. Methods. 16 diabetic pts were randomized to treatment (n=8)(continuous infusion or QID sub q administration of maximally tolerated OCT doses ranging from 600-3000 μg/day) or control (n=8)(conventional DM management) groups for 15 months. Pts received clinical and biochemical assessment at entry and at 3 month intervals. Ophthalmic assessment occurred at entry and at 1 month intervals. Seven fields per eye were assessed for characterization of retinopathy and grading using a modified ETDRS grading system. Results. In pts treated with OCT, GH levels (area under curve) were reduced by 33% (p1c, over 15 months was improved in the OCT treated group (6.4±0.9%) compared to the control group (8.1±1.2%)(p

UR - http://www.scopus.com/inward/record.url?scp=0342542702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342542702&partnerID=8YFLogxK

M3 - Article

VL - 37

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -